Spectrum Pharmaceuticals Inc Quick Ratio (SPPI) starting from the first quarter 2023 to first quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Spectrum Pharmaceuticals Inc   (NASDAQ: SPPI)

Spectrum Pharmaceuticals Inc 's Quick Ratio

SPPI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Spectrum Pharmaceuticals Inc 's Cash & cash equivalent, this led to improvement in Spectrum Pharmaceuticals Inc 's Quick Ratio to 1.44, Quick Ratio remained below Spectrum Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 420 other companies have achieved higher Quick Ratio than Spectrum Pharmaceuticals Inc in first quarter 2023. While Quick Ratio total ranking in the first quarter 2023 has deteriorated compared to the prior quarter from 1447 to 1779.

Explain Quick Ratio?
How much Cash & cash equivalents SPPI´s has?
What are SPPI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SPPI Quick Ratio (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1
Y / Y Current Liabilities Change -0.83 % 109.17 % -13.35 % -27.62 % -17.25 %
Y / Y Cash & cash equivalent Change -37.08 % -25.39 % -24.96 % -57.21 % -45.22 %
Quick Ratio MRQ 1.44 0.67 2.02 1.66 2.28
SPPI's Total Ranking # 1779 # 1447 # 1479 # 1631 # 1365
Seq. Current Liabilities Change -65.08 % 124.36 % 20.91 % 4.68 % -26.34 %
Seq. Cash & cash equivalent Change -25.25 % -25.09 % 47.52 % -23.82 % -11.36 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 421
Healthcare Sector # 741
Overall Market # 1779


Quick Ratio Statistics
High Average Low
5.18 2.35 1.09
(Sep 30 2019)   (Sep 30 2012)




Financial Statements
Spectrum Pharmaceuticals Inc 's Current Liabilities $ 39 Millions Visit SPPI's Balance sheet
Spectrum Pharmaceuticals Inc 's Cash & cash equivalent $ 56 Millions Visit SPPI's Balance sheet
Source of SPPI's Sales Visit SPPI's Sales by Geography


Cumulative Spectrum Pharmaceuticals Inc 's Quick Ratio

SPPI's Quick Ratio for the trailling 12 Months

SPPI Quick Ratio

 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 16.7 % 12.41 % -14.02 % -12.01 % -4.28 %
Y / Y Cash & cash equivalent TTM Growth -37.91 % -40.19 % -43.64 % -44.08 % -30.88 %
Quick Ratio TTM 1.24 1.38 1.96 2.05 2.34
Total Ranking TTM # 4635 # 4398 # 1113 # 1349 # 4362
Seq. Current Liabilities TTM Growth -0.14 % 31.74 % -4.01 % -7.59 % -3.81 %
Seq. Cash & cash equivalent TTM Growth -9.95 % -7.14 % -8.52 % -18.84 % -13.25 %

Quick ratio ranking by company, industry and sector >> Back to SPPI Financial Strength Comparisons >> Go to Compare SPPI Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in SPPI's Current Liabilities to $38.88 millions, cumulative Quick Ratio to 1.24 below the SPPI average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 590 other companies have achieved higher Quick Ratio than Spectrum Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 4398 to 4635.

Explain Quick Ratio?
How much Cash & cash equivalents SPPI´s has?
What are SPPI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 591
Healthcare Sector # 1175
Within the Market # 4635


trailing twelve months Quick Ratio Statistics
High Average Low
4.45 2.44 1.31
(Dec 31 2019)   (Jun 30 2015)




Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2023 MRQ Cash & cash equivalentMar 31 2023 MRQ Current Liabilities
Puretech Health Plc  3.95 $ 202.827  Millions$ 51.370  Millions
Nuvectis Pharma inc   3.93 $ 15.468  Millions$ 3.934  Millions
Repare Therapeutics Inc   3.88 $ 314.124  Millions$ 80.935  Millions
Xoma Royalty Corporation  3.86 $ 44.300  Millions$ 11.462  Millions
Unity Biotechnology Inc   3.82 $ 83.392  Millions$ 21.858  Millions
Decibel Therapeutics Inc   3.79 $ 87.941  Millions$ 23.179  Millions
Hyperion Defi inc   3.79 $ 18.586  Millions$ 4.901  Millions
Damora Therapeutics Inc   3.79 $ 53.247  Millions$ 14.063  Millions
Innoviva Inc   3.78 $ 144.049  Millions$ 38.137  Millions
Genprex Inc   3.74 $ 18.083  Millions$ 4.835  Millions
Canton Strategic Holdings Inc   3.71 $ 3.569  Millions$ 0.961  Millions
Vincerx Pharma Inc   3.71 $ 39.768  Millions$ 10.712  Millions
Tempest Therapeutics Inc   3.71 $ 22.925  Millions$ 6.186  Millions
Exicure Inc   3.65 $ 9.960  Millions$ 2.729  Millions
Vistagen Therapeutics Inc   3.64 $ 16.638  Millions$ 4.567  Millions
Arcturus Therapeutics Holdings Inc   3.64 $ 327.935  Millions$ 90.130  Millions
Gain Therapeutics inc  3.62 $ 17.816  Millions$ 4.922  Millions
Alterity Therapeutics Limited  3.60 $ 10.510  Millions$ 2.920  Millions
Galera Therapeutics Inc   3.60 $ 47.751  Millions$ 13.266  Millions
Abivax Sa  3.60 $ 282.175  Millions$ 78.447  Millions
Y mabs Therapeutics inc   3.57 $ 92.629  Millions$ 25.920  Millions
Bio path Holdings inc   3.52 $ 6.731  Millions$ 1.910  Millions
Revance Therapeutics Inc   3.52 $ 274.224  Millions$ 77.985  Millions
Adagene Inc   3.49 $ 109.934  Millions$ 31.456  Millions
Longeveron Inc   3.49 $ 10.593  Millions$ 3.039  Millions
Proqr Therapeutics N v   3.48 $ 133.196  Millions$ 38.307  Millions
Acurx Pharmaceuticals inc   3.46 $ 7.179  Millions$ 2.074  Millions
G1 Therapeutics Inc   3.45 $ 116.317  Millions$ 33.690  Millions
Vertex Pharmaceuticals Inc  3.44 $ 10,414.100  Millions$ 3,026.200  Millions
Regulus Therapeutics Inc   3.44 $ 30.308  Millions$ 8.822  Millions

Date modified: 2026-09-26T07:17:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.